Literature DB >> 15923254

Antibiotic allergy in cystic fibrosis.

J S Parmar1, S Nasser.   

Abstract

Allergic reactions to antibiotics are more common in cystic fibrosis (CF) than in the general population. This in part is due to the improving survival in adults with CF and the increased use of high dose intravenous antibiotics. While some are immediate anaphylaxis type (IgE mediated) reactions, the majority are late onset and may have non-specific features such as rash and fever. Piperacillin has consistently been found to have the highest rate of reported reactions (30-50%). There is a low risk of cross reactions between penicillins and other non-beta-lactam classes of antibiotics in penicillin skin prick positive patients. Carbapenems should only be used with extreme caution in patients with positive skin prick tests to penicillin. However, aztreonam can be used safely in patients who are penicillin allergic with positive skin prick reactions. The aminoglycosides are a relatively uncommon cause of allergic reactions, but patients who react to one member of the family may cross react with other aminoglycosides. Desensitisation relies on the incremental introduction of small quantities of the allergen and has been used for penicillins, ceftazidime, tobramycin and ciprofloxacin and must be repeated before each course. Personalized cards should be regularly updated for patients who develop allergic reactions. Written instructions on the emergency treatment of allergic reactions should be provided to patients self-administering intravenous antibiotics at home. Further research is required to identify risk factors and predictors for antibiotic allergy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15923254      PMCID: PMC1747437          DOI: 10.1136/thx.2004.027953

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

Review 1.  The pathogenic consequences of a single mutated CFTR gene.

Authors:  U Griesenbach; D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  The innate immune system in cystic fibrosis lung disease.

Authors:  R Bals; D J Weiner; J M Wilson
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

3.  Intravenous desensitization to ceftazidime in cystic fibrosis patients.

Authors:  S Ghosal; C J Taylor
Journal:  J Antimicrob Chemother       Date:  1997-04       Impact factor: 5.790

4.  Immunologic response to different determinants of benzylpenicillin, amoxicillin, and ampicillin. Comparison between urticaria and anaphylactic shock.

Authors:  M J Torres; C Mayorga; R Pamies; J L Rodriquez; C Juarez; A Romano; M Blanca
Journal:  Allergy       Date:  1999-09       Impact factor: 13.146

5.  Ciprofloxacin desensitization in a patient with cystic fibrosis.

Authors:  R R Lantner
Journal:  J Allergy Clin Immunol       Date:  1995-12       Impact factor: 10.793

6.  Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses.

Authors:  A Romano; C Mayorga; M J Torres; M C Artesani; R Suau; F Sánchez; E Pérez; A Venuti; M Blanca
Journal:  J Allergy Clin Immunol       Date:  2000-12       Impact factor: 10.793

7.  Antibiotic hypersensitivity reactions in cystic fibrosis.

Authors:  R Wills; R L Henry; J L Francis
Journal:  J Paediatr Child Health       Date:  1998-08       Impact factor: 1.954

8.  Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study.

Authors:  R Mahadeva; K Webb; R C Westerbeek; N R Carroll; M E Dodd; D Bilton; D A Lomas
Journal:  BMJ       Date:  1998-06-13

9.  Tobramycin-induced hypersensitivity reaction.

Authors:  J S Schretlen-Doherty; W G Troutman
Journal:  Ann Pharmacother       Date:  1995 Jul-Aug       Impact factor: 3.154

Review 10.  Structure and function of the CFTR chloride channel.

Authors:  D N Sheppard; M J Welsh
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

View more
  18 in total

1.  Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.

Authors:  Kim Thomsen; Lars Christophersen; Peter Østrup Jensen; Thomas Bjarnsholt; Claus Moser; Niels Høiby
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis.

Authors:  Sabah El-Ghaiesh; Manal M Monshi; Paul Whitaker; Rosalind Jenkins; Xiaoli Meng; John Farrell; Ayman Elsheikh; Daniel Peckham; Neil French; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2012-02-27       Impact factor: 4.030

Review 3.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

4.  Hepatotoxicity induced by trimethoprim-sulfamethoxazole in a child with cystic fibrosis.

Authors:  Ibrahim Abdulhamid; Victoria Tutag Lehr
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

5.  Evaluation of Frequency and Characteristics of Drug Allergy in Pediatric Patients with Cystic Fibrosis.

Authors:  Zeynep Şengül Emeksiz; Pınar Metbulut; Şule Selin Akyan Soydaş; Gökçen Tuğcu; Güzin Cinel; Emine Dibek Mısırlıoğlu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2022-05-18       Impact factor: 0.885

Review 6.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 7.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.

Authors:  Alex Horsley; Andrew M Jones; Robert Lord
Journal:  Cochrane Database Syst Rev       Date:  2016-01-20

8.  A multifunctional bispecific antibody against Pseudomonas aeruginosa as a potential therapeutic strategy.

Authors:  Iram J Haq; Aaron Gardner; Malcolm Brodlie
Journal:  Ann Transl Med       Date:  2016-01

9.  Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics.

Authors:  Silvia Caimmi; Céline Sanfiorenzo; Davide Caimmi; Philippe-Jean Bousquet; Raphael Chiron; Pascal Demoly
Journal:  Clin Transl Allergy       Date:  2012-06-14       Impact factor: 5.871

10.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Linsey Abbott; Amanda Plummer; Zhe Hui Hoo; Martin Wildman
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.